Equity, expense, and expertise in biologic commissioning: adding the patient to the equation
{{output}}
Introduction: Immune-mediated inflammatory diseases (IMIDs) are increasingly managed effectively with biologic medicines. However, with relatively high unit costs, there remains a meaningful pressure to ensure streamlined, equita... ...
